<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05620836</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 54707-302</org_study_id>
    <nct_id>NCT05620836</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)</brief_title>
  <acronym>STOP-HS2</acronym>
  <official_title>A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707)&#xD;
      in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week&#xD;
      placebo-controlled period, followed by a 42-week extension period.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 22, 2023</start_date>
  <completion_date type="Anticipated">January 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 11, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized 1:1:1 to Povorcitinib Dose A, Povorcitinib Dose B, or Placebo once a day (QD); participants who complete the placebo-controlled (PC) 12-week period may continue to a 42-week extension (EXT) period with Povorcitinib (Dose A or Dose B) QD.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response (HiSCR)</measure>
    <time_frame>Week 12</time_frame>
    <description>HiSCR is defined as at least a 50% reduction from baseline in the total abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who achieve Hidradenitis Suppurativa Clinical Response 75 (HiSCR75)</measure>
    <time_frame>Week 12</time_frame>
    <description>HiSCR75 is defined as at least a 75% reduction from baseline in the total abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with flare</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Participants who experience at least 1 flare over 12 weeks; flare is defined as at least a 25% increase in the total abscess and inflammatory nodule count with a minimum increase of 2 relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with a ≥ 3-point decrease in Skin Pain Numeric Rating Scale (NRS) score among participants with baseline Skin Pain NRS score ≥ 3</measure>
    <time_frame>Week 12</time_frame>
    <description>Participants with a Skin Pain score of at least 3 at baseline and who experience at least a 3-point decrease in Skin Pain score at Week 12, relative to baseline. Skin Pain is an 11-point NRS, ranging from 0 (no skin pain) to 10 (worst skin pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who achieve Skin Pain NRS30 at Week 12 among participants with baseline Skin Pain NRS score ≥ 3.</measure>
    <time_frame>Week 12</time_frame>
    <description>Participants with a Skin Pain score of at least 3 at baseline and who achieve at Week 12 Skin Pain NRS30, defined as at least a 30% reduction and at least 1-unit reduction from baseline in the Skin Pain NRS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with a ≥ 4-point increase from baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) score</measure>
    <time_frame>Week 12</time_frame>
    <description>Participants with a baseline FACIT-F score ≤ 48 and who experience at least a 4-point increase in FACIT-F score at Week 12, relative to baseline. The FACIT-F scale is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the past 7 days, with scores ranging from 0 (worst fatigue) to 52 (no fatigue).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in Dermatology Life Quality Index (DLQI) score</measure>
    <time_frame>54 weeks</time_frame>
    <description>The DLQI is a skin disease specific questionnaire aimed at the evaluation of how symptoms and treatment affect participants' health-related quality of life (QoL). The DLQI total score ranges from 0 to 30, with higher scores indicating lower skin health related QoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in abscess count</measure>
    <time_frame>54 weeks</time_frame>
    <description>Defined as mean change of abscess(es) count relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in abscess count</measure>
    <time_frame>54 weeks</time_frame>
    <description>Percent Change from baseline in number of abscess(es)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in inflammatory nodule count</measure>
    <time_frame>54 weeks</time_frame>
    <description>Defined as mean change of inflammatory nodule count relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in inflammatory nodule count</measure>
    <time_frame>54 weeks</time_frame>
    <description>Defined as percent change from baseline in number of inflammatory nodule(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in draining tunnel count</measure>
    <time_frame>54 weeks</time_frame>
    <description>Defined as mean change of draining tunnel count relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in draining tunnel count</measure>
    <time_frame>54 weeks</time_frame>
    <description>Defined as Percent change from baseline in number of draining tunnel(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Period: Proportion of participants who achieve HiSCR</measure>
    <time_frame>Week 24</time_frame>
    <description>HiSCR is defined as at least a 50% reduction from baseline in the total abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Period: Proportion of participants who achieve HiSCR75</measure>
    <time_frame>Week 24</time_frame>
    <description>HiSCR75 is defined as at least a 75% reduction from baseline in the total abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Period: Proportion of participants with flare</measure>
    <time_frame>From Week 12 through Week 24</time_frame>
    <description>Participants who experience at least 1 flare over the period under assessment; flare is defined as at least a 25% increase in the total abscess and inflammatory nodule count with a minimum increase of 2 relative to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Period: Proportion of participants who achieved Skin Pain NRS30 among participants with baseline Skin Pain NRS score ≥ 3.</measure>
    <time_frame>Week 24</time_frame>
    <description>Skin Pain NRS30 defined as at least a 30% reduction and at least 1-unit reduction from baseline in the Skin Pain NRS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Period: Proportion of participants who achieve HiSCR</measure>
    <time_frame>Week 54</time_frame>
    <description>HiSCR is defined as at least a 50% reduction from baseline in the total abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Period: Proportion of participants who achieve HiSCR75</measure>
    <time_frame>Week 54</time_frame>
    <description>HiSCR75 is defined as at least a 75% reduction from baseline in the total abscess and inflammatory nodule count, with no increase from baseline in abscess or draining tunnel count.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Period: Proportion of participants with flare</measure>
    <time_frame>From Week 12 through Week 54</time_frame>
    <description>Participants who experience at least 1 flare over the period under assessment; flare is defined as at least a 25% increase in the total abscess and inflammatory nodule count with a minimum increase of 2 relative to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Period: Proportion of participants who achieved Skin Pain NRS30 among participants with baseline Skin Pain NRS score ≥ 3.</measure>
    <time_frame>Week 54</time_frame>
    <description>Participants with a Skin Pain score of at least 3 at baseline and who achieve Skin Pain NRS30, defined as at least a 30% reduction and at least 1-unit reduction from baseline in the Skin Pain NRS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Period: Proportion of participants who achieve maintenance of HiSCR or greater response at each visit</measure>
    <time_frame>From Week 12 through Week 54</time_frame>
    <description>Maintenance of response defined as participants who achieve HiSCR at Week 12 and maintain it or achieve greater response at each visit during the EXT period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extension Period: Proportion of participants who achieve maintenance of HiSCR75 or greater response at each visit</measure>
    <time_frame>From Week 12 through Week 54</time_frame>
    <description>Maintenance of response defined as participants who achieve HiSCR75 at Week 12 and maintain it or achieve greater response at each visit during the EXT period.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Hidradenitis Suppurativa (HS)</condition>
  <arm_group>
    <arm_group_label>Povorcitinib Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Povorcitinib Dose A for 54 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Povorcitinib Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Povorcitinib Dose B for 54 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive Placebo for 12 weeks, followed by Povorcitinib (Dose A or Dose B) for 42 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Povorcitinib</intervention_name>
    <description>Oral, Tablet</description>
    <arm_group_label>Povorcitinib Dose A</arm_group_label>
    <arm_group_label>Povorcitinib Dose B</arm_group_label>
    <other_name>INCB054707</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral, Tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female participants ≥ 18 years of age.&#xD;
&#xD;
          -  Diagnosis of moderate to severe HS ≥ 3 months prior to Screening visit.&#xD;
&#xD;
          -  HS lesions present in ≥ 2 distinct anatomic areas, 1 of which must be at least Hurley&#xD;
             Stage II or Hurley Stage III, at both the Screening and Baseline visits.&#xD;
&#xD;
          -  Total abscess and inflammatory nodule (AN) count ≥ 5 at both the Screening and&#xD;
             Baseline visits.&#xD;
&#xD;
          -  History of inadequate response to an appropriate course of at least 1 conventional&#xD;
             systemic therapy for HS (or demonstrated intolerance to, or have a contraindication&#xD;
             to, a conventional systemic therapy for HS)&#xD;
&#xD;
          -  Agree to not use certain topical antiseptics on the areas affected by HS lesions&#xD;
             during the placebo-controlled period.&#xD;
&#xD;
          -  Willingness to avoid pregnancy or fathering children.&#xD;
&#xD;
          -  Other inclusion criteria apply.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Draining tunnel count of &gt; 20 at Screening or Baseline visits.&#xD;
&#xD;
          -  Women who are pregnant (or who are considering pregnancy) or breastfeeding.&#xD;
&#xD;
          -  Medical history including thrombocytopenia, coagulopathy or platelet dysfunction;&#xD;
             venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke,&#xD;
             moderate to severe heart failure, cerebrovascular accident, myocardial infarction, or&#xD;
             other significant cardiovascular diseases; Q-wave interval abnormalities; disseminated&#xD;
             herpes zoster or dermatomal herpes zoster; disseminated herpes simplex;&#xD;
             chronic/recurrent infections; malignancies.&#xD;
&#xD;
          -  Evidence of infection with TB, HBV, HCV or HIV.&#xD;
&#xD;
          -  History of failure to JAK inhibitor treatment of any inflammatory disease.&#xD;
&#xD;
          -  Laboratory values outside of the protocol-defined ranges.&#xD;
&#xD;
          -  Other exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>eumedinfo@incyte.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Investigative Site US223</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site US226</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site US222</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site US228</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site US227</name>
      <address>
        <city>Margate</city>
        <state>Florida</state>
        <zip>33063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site US200</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site US201</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site US220</name>
      <address>
        <city>West Dundee</city>
        <state>Illinois</state>
        <zip>60118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site US206</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site US207</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site US229</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site US224</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site US208</name>
      <address>
        <city>Beverly</city>
        <state>Massachusetts</state>
        <zip>01915</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site US225</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site US221</name>
      <address>
        <city>Quincy</city>
        <state>Massachusetts</state>
        <zip>02169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site US203</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site AU206</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>04102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site AU207</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>04102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site CA206</name>
      <address>
        <city>St-jerome</city>
        <state>Quebec</state>
        <zip>J7Z 7E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site DK200</name>
      <address>
        <city>AaRHUS N</city>
        <zip>08200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site DK201</name>
      <address>
        <city>Roskilde</city>
        <zip>04000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site FR206</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site DE208</name>
      <address>
        <city>Gottingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site DE206</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site ES204</name>
      <address>
        <city>Madrid</city>
        <zip>28005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site ES205</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site GB202</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2GW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site GB204</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site GB203</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>November 10, 2022</study_first_submitted>
  <study_first_submitted_qc>November 10, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2022</study_first_posted>
  <last_update_submitted>March 1, 2023</last_update_submitted>
  <last_update_submitted_qc>March 1, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hidradenitis Suppurativa</keyword>
  <keyword>HS</keyword>
  <keyword>INCB054707</keyword>
  <keyword>Povorcitinib</keyword>
  <keyword>Acne inversa</keyword>
  <keyword>Hidradenitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hidradenitis Suppurativa</mesh_term>
    <mesh_term>Hidradenitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.</ipd_time_frame>
    <ipd_access_criteria>Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.incyte.com/our-company/compliance-and-transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

